$XTALPI(02228.HK) Just looking at the few companies incubated by Jingtai, Jingtai is at the foot of the mountain.
The first innovative drug of Company J, incubated by Jingtai, will file for NDA and be launched in 2026, setting a record of 6 years from discovery to market.
Company L, another incubated firm, has completely cured chronic blood tumors and chronic granulocytic leukemia with ultra-low doses in two batches. Recently, the first patient with lupus erythematosus achieved complete remission... This is a drug with significant BD potential.
Company X, incubated by Jingtai, developed the world's first targeted drug for diffuse gastric cancer in just four years and received FDA orphan drug designation and fast-track approval. It is currently undergoing Phase I clinical trials at Peking University Cancer Hospital.
What we need to do is wait and hold patiently, because once this materializes, all skepticism will lead to a re-evaluation and major transformation of traditional drug discovery.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
